Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−104.78 M USD
5.00 M USD
About Adlai Nortye Ltd.
Sector
CEO
Yang Lu
Website
Headquarters
Hangzhou
Founded
2018
FIGI
BBG01HP11SV4
Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.